<p>雖然關於 “下一代” 減肥療法這個術語還存在一些歧義，但有一點是清楚的：與當前一代減肥藥物不同，理想的減肥藥物在治療過程中不會導致患者失去肌肉質量。</p>
<p>首家開發出更理想的減肥藥物的公司可能會獲得可觀的利潤。目前已經有幾家公司在開發候選藥物，這些藥物可能符合這一標準，因此讓我們分別來看看它們，因為它們都值得購買。</p>
<h2>1. 禮來</h2>
<p>作為減肥市場的一員，<strong>禮來</strong>（LLY 0.18%）以其拳頭產品 Zepbound 而聞名，該藥用於治療肥胖症。僅在第二季度，Zepbound 的銷售額就超過了 12 億美元。但該公司正在心臟代謝醫學領域進行大量的研發活動，儘管有許多下一代候選藥物，但其中一種尤為有前途。</p>
<p>目前，禮來正在進行一項第 2 期臨牀試驗，研究其名為 bimagrumab 的抗體是否有助於減肥，無論是單獨使用還是與 <strong>諾和諾德</strong> 的藥物 semaglutide（常用的商品名為 Ozempic 和 Wegovy）聯合使用。具體而言，該試驗旨在研究 bimagrumab 是否能在與 semaglutide 治療期間保護肌肉質量，甚至在患者整體體重下降的情況下，可能會增加肌肉質量。</p>
<p>有理由相信禮來將會找到其期望的有益影響。在之前由第三方研究人員進行的一項研究中，研究了該候選藥物對患有 2 型糖尿病和肥胖症的患者的影響，結果令人矚目。經過 48 周的治療，患者平均減少了 20.5% 的總脂肪質量，同時增加了 3.6% 的瘦體重，顯著減少了腰圍，總體體重減輕了 6.5%，還改善了血糖水平。在治療組和安慰劑組之間，出現副作用的比率以及副作用的強度相當相似。</p>
<p>預計禮來對 bimagrumab 的研究將於 2025 年中期結束。如果結果與其他試驗一致，該公司無疑將希望將該項目推進到第 3 期研究，然後進行商業化，假設監管機構批准。</p>
<p>如果最終獲得銷售批准，它可能不會在面對堅決反對的情況下難以獲得市場份額。一種有效清除腹部脂肪並略微促進肌肉生長的減肥藥物顯然是一種贏家，到目前為止市場上沒有其他產品可以媲美。而且，當與禮來大力努力研發其他強化抗肥胖藥物的努力相結合時，如果第 2 期結果看起來令人滿意，其股價可能會迎來重大推動，這是現在購買該股票的另一個理由。</p>
<h2>2. BioAge Labs</h2>
<p><strong>BioAge Labs</strong>（BIOA 4.94%）仍在努力推出其首個藥物，但其主力候選藥物可能比當今的減肥藥物具有一系列引人注目的優勢。該項目名為 azelaprag，也可能幫助患者減肥的同時保留甚至增加其瘦肌肉質量。</p>
<p>目前，azelaprag 正處於第 2 期臨牀試驗階段，正在測試與禮來和諾和諾德生產的拳頭減肥藥物的聯合使用。其第 1b 期臨牀試驗的結果令人鼓舞。</p>
<p>在一項對 21 名長期卧牀的老年人進行的為期 10 天的研究中，只有治療組中的 11 名患者中有 1 名患者的肌肉質量下降，而安慰劑組中有 10 名患者中有 8 名患者的肌肉質量下降。他們的肌肉尺寸也比接受安慰劑的患者明顯保持得更好。特別是，他們的大腿圍尺寸平均增加了兩倍。</p>
<p>事實上，一些接受 azelaprag 的患者實際上看到其部分肌肉尺寸略微增加。動物模型的臨牀前數據還表明，該候選藥物通過促使一系列有利的代謝變化具有強大的減肥效果，但這些發現需要在人類中得到複製後才值得激動。</p>
<p>BioAge 聲稱 azelaprag 能夠取得這些令人印象深刻的成就，因為它導致的生理效應與體育鍛煉的效應重疊。如果這是真的，除非出現重大安全信號，並且假設剩餘的臨牀試驗按計劃進行，很容易看出它可能正在研發一種成功的藥物。基於這一潛力，購買該股票是值得的，只要您目前保持小額投資，並且願意投資於一個風險極高的未盈利生物技術股票。</p>
<p>但不要讓這家生物技術公司漫長的盈利之路使您感到過於沮喪。10 月 1 日，它結束了首次公開發行（IPO）和同時進行的私募股份發行，籌集了超過 2.38 億美元的總收入。其過去 12 個月的運營費用僅為 5150 萬美元，因此即使考慮到不久的將來運行中後期和晚期臨牀試驗的更高成本，它至少還有幾年時間不需要籌集更多資金。</p>

禮來

<p>這篇文章討論了兩家有前景的減肥股票：禮來和 BioAge Labs。禮來的 Zepbound 已經產生了顯著的銷售額，其 bimagrumab 候選藥正在進行第二階段試驗，旨在在減肥過程中保持肌肉質量。BioAge Labs 正在開發 azelaprag，該藥在保持肌肉的同時促進減肥方面顯示出潛力，目前正在進行第二階段試驗。這兩家公司在減肥市場上處於增長的位置，使它們的股票對投資者具有吸引力</p>

<p>While there's some ambiguity about the term &#34;next generation&#34; when it comes to weight loss therapies, one thing is clear: Unlike the current generation of weight loss drugs, the ideal weight loss medicines won't cause patients to lose muscle mass while they're being treated.</p>
<div class="lb-trans"><p>雖然關於 “下一代” 減肥療法這個術語還存在一些歧義，但有一點是清楚的：與當前一代減肥藥物不同，理想的減肥藥物在治療過程中不會導致患者失去肌肉質量。</p>
</div><p>The first business to develop one of those more ideal weight loss drugs will likely see a significant windfall. There are already a couple of companies in particular that have candidates in development which might fit that bill, so let's examine each, as they're both worth buying.</p>
<div class="lb-trans"><p>首家開發出更理想的減肥藥物的公司可能會獲得可觀的利潤。目前已經有幾家公司在開發候選藥物，這些藥物可能符合這一標準，因此讓我們分別來看看它們，因為它們都值得購買。</p>
</div><h2>1. Eli Lilly</h2>
<div class="lb-trans"><h2>1. 禮來</h2>
</div><p>As a player in the weight loss market, <strong>Eli Lilly</strong>(LLY 0.18%) is best known for its blockbuster drug Zepbound, which is indicated to treat obesity. In the second quarter alone, sales of Zepbound were worth more than $1.2 billion. But the company is in the process of doing a lot more research and development (R&amp;D) activity within cardiometabolic medicine, and, though it has many next-generation candidates, one stands out as being especially promising.</p>
<div class="lb-trans"><p>作為減肥市場的一員，<strong>禮來</strong>（LLY 0.18%）以其拳頭產品 Zepbound 而聞名，該藥用於治療肥胖症。僅在第二季度，Zepbound 的銷售額就超過了 12 億美元。但該公司正在心臟代謝醫學領域進行大量的研發活動，儘管有許多下一代候選藥物，但其中一種尤為有前途。</p>
</div><p>Lilly is currently doing a phase 2 clinical trial investigating whether its antibody called bimagrumab is helpful for weight loss, either when used alone, or when used in conjunction with <strong>Novo Nordisk</strong>'s drug semaglutide, which is commonly known by the trade names Ozempic and Wegovy. Specifically, the trial is looking at whether bimagrumab is capable of protecting muscle mass during treatment with semaglutide, or potentially even increasing it despite the patient's weight falling overall.</p>
<div class="lb-trans"><p>目前，禮來正在進行一項第 2 期臨牀試驗，研究其名為 bimagrumab 的抗體是否有助於減肥，無論是單獨使用還是與 <strong>諾和諾德</strong> 的藥物 semaglutide（常用的商品名為 Ozempic 和 Wegovy）聯合使用。具體而言，該試驗旨在研究 bimagrumab 是否能在與 semaglutide 治療期間保護肌肉質量，甚至在患者整體體重下降的情況下，可能會增加肌肉質量。</p>
</div><p>There's reason to believe that Lilly will find the beneficial impacts it's looking for here. In a prior phase 2 study conducted by third-party researchers investigating the effects of the candidate on patients with both type 2 diabetes and obesity, the results were phenomenal. After 48 weeks of treatment, patients lost, on average, 20.5% of their total fat mass while actually gaining 3.6% of their lean mass, significantly trimming their waistlines, reducing their total body weight by 6.5%, and improving their blood glucose levels, too. Rates of experiencing side effects, as well as the intensity of side effects, were fairly similar between the treatment and placebo groups.</p>
<div class="lb-trans"><p>有理由相信禮來將會找到其期望的有益影響。在之前由第三方研究人員進行的一項研究中，研究了該候選藥物對患有 2 型糖尿病和肥胖症的患者的影響，結果令人矚目。經過 48 周的治療，患者平均減少了 20.5% 的總脂肪質量，同時增加了 3.6% 的瘦體重，顯著減少了腰圍，總體體重減輕了 6.5%，還改善了血糖水平。在治療組和安慰劑組之間，出現副作用的比率以及副作用的強度相當相似。</p>
</div><p>Lilly's study of bimagrumab is expected to wrap up in mid-2025. If the results agree with the other trial's, the business will doubtlessly want to advance the program into phase 3 studies and then commercialization, assuming regulators give it the green light.</p>
<div class="lb-trans"><p>預計禮來對 bimagrumab 的研究將於 2025 年中期結束。如果結果與其他試驗一致，該公司無疑將希望將該項目推進到第 3 期研究，然後進行商業化，假設監管機構批准。</p>
</div><p>If it is eventually approved for sale, it will probably not struggle to gain market share, even in the face of determined opposition. A weight loss medicine that efficiently liquidates fat around the abdomen while slightly boosting muscle growth is an obvious winner, and so far there's nothing else on the market that can compare. And, when paired with Lilly's extensive efforts to make other souped-up anti-obesity medicines, its stock could see a significant catalyst if the phase 2 results look favorable, so it's one more reason to buy the stock now.</p>
<div class="lb-trans"><p>如果最終獲得銷售批准，它可能不會在面對堅決反對的情況下難以獲得市場份額。一種有效清除腹部脂肪並略微促進肌肉生長的減肥藥物顯然是一種贏家，到目前為止市場上沒有其他產品可以媲美。而且，當與禮來大力努力研發其他強化抗肥胖藥物的努力相結合時，如果第 2 期結果看起來令人滿意，其股價可能會迎來重大推動，這是現在購買該股票的另一個理由。</p>
</div><h2>2. BioAge Labs</h2>
<div class="lb-trans"><h2>2. BioAge Labs</h2>
</div><p><strong>BioAge Labs</strong>(BIOA 4.94%) is still working on launching its first drug, but its lead candidate could offer a highly compelling set of advantages over today's crop of weight loss drugs. That program, called azelaprag, could also potentially help patients to lose weight while preserving or perhaps even augmenting their lean muscle mass.</p>
<div class="lb-trans"><p><strong>BioAge Labs</strong>（BIOA 4.94%）仍在努力推出其首個藥物，但其主力候選藥物可能比當今的減肥藥物具有一系列引人注目的優勢。該項目名為 azelaprag，也可能幫助患者減肥的同時保留甚至增加其瘦肌肉質量。</p>
</div><p>At the moment, azelaprag is in phase 2 clinical trials testing it as a combination with the blockbuster weight loss drugs produced by both Eli Lilly and Novo Nordisk. The results from its phase 1b clinical trial are promising.</p>
<div class="lb-trans"><p>目前，azelaprag 正處於第 2 期臨牀試驗階段，正在測試與禮來和諾和諾德生產的拳頭減肥藥物的聯合使用。其第 1b 期臨牀試驗的結果令人鼓舞。</p>
</div><p>In a 10-day study of 21 seniors confined to bed rest -- as in, the patients weren't allowed to leave their bed for more than a week -- only one of the 11 patients in the treatment group experienced a decline in their muscle quality, compared to eight out of the 10 in the placebo group. Their muscles also retained their dimensions significantly better than the patients who were administered the placebo. In particular, their thigh circumference measurement was two times as, on average.</p>
<div class="lb-trans"><p>在一項對 21 名長期卧牀的老年人進行的為期 10 天的研究中，只有治療組中的 11 名患者中有 1 名患者的肌肉質量下降，而安慰劑組中有 10 名患者中有 8 名患者的肌肉質量下降。他們的肌肉尺寸也比接受安慰劑的患者明顯保持得更好。特別是，他們的大腿圍尺寸平均增加了兩倍。</p>
</div><p>In fact, some of the patients getting azelaprag actually saw some of their muscle dimensions increase a small amount. Pre-clinical data from animal models also suggest that the candidate has a potent weight loss effect via prompting a slew of favorable metabolic changes, but those findings will need to be replicated in humans before they're worth getting excited about.</p>
<div class="lb-trans"><p>事實上，一些接受 azelaprag 的患者實際上看到其部分肌肉尺寸略微增加。動物模型的臨牀前數據還表明，該候選藥物通過促使一系列有利的代謝變化具有強大的減肥效果，但這些發現需要在人類中得到複製後才值得激動。</p>
</div><p>BioAge claims that azelaprag is capable of these impressive accomplishments because it leads to physiological effects that overlap the effects of physical exercise. If that's true, barring any major safety signals and assuming that the remaining clinical trials go as planned, it's easy to see how it could be working on a home-run drug here. It's worth buying the stock on the basis of that potential, as long as you keep your exposure small for now, and as long as you're comfortable with investing in a highly risky pre-revenue biotech stock.</p>
<div class="lb-trans"><p>BioAge 聲稱 azelaprag 能夠取得這些令人印象深刻的成就，因為它導致的生理效應與體育鍛煉的效應重疊。如果這是真的，除非出現重大安全信號，並且假設剩餘的臨牀試驗按計劃進行，很容易看出它可能正在研發一種成功的藥物。基於這一潛力，購買該股票是值得的，只要您目前保持小額投資，並且願意投資於一個風險極高的未盈利生物技術股票。</p>
</div><p>But don't let this biotech's long road to revenue be too discouraging. On Oct. 1, it closed its initial public offering (IPO) and a concurrent private placement of its shares, raising gross proceeds of more than $238 million. Its trailing-12-month operating expenses were just $51.5 million, so it has at least a couple of years before it'll need to raise more cash, even when considering the higher costs of running mid- and late-stage clinical trials in the near future.</p>
<div class="lb-trans"><p>但不要讓這家生物技術公司漫長的盈利之路使您感到過於沮喪。10 月 1 日，它結束了首次公開發行（IPO）和同時進行的私募股份發行，籌集了超過 2.38 億美元的總收入。其過去 12 個月的運營費用僅為 5150 萬美元，因此即使考慮到不久的將來運行中後期和晚期臨牀試驗的更高成本，它至少還有幾年時間不需要籌集更多資金。</p>
</div>

兩隻值得現在購買的下一代減肥股票